Compare Docusign Inc (DOCU) vs Hims and Hers Health Inc (HIMS) Price & Performance

DOCU trades at $60.26, up 5.91% today, reflecting strong momentum after consecutive earnings beats. The stock shows bullish technical signals with support at $58 and resistance at $61. Revenue grew to $2.98B in 2025, with net income surging to $1.07B, though cash flow turned negative. Analyst consensus is mixed with a $55.40 price target below the current price, indicating caution despite recent strength.

Outlook balances robust profitability and growth against high valuation and cash flow concerns. The stock offers upside if earnings momentum continues but faces risks from competitive pressures and reliance on subscription renewals. Institutional activity shows mixed signals with some funds reducing stakes.

Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.

The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.